Plus Exemestane News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plus Exemestane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plus Exemestane Today - Breaking & Trending Today

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

Published: April 29, 2024

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...

Source: marketscreener.com

Related Topics:

United KingdomIsrael GeneralDaiichi SankyoTrastuzumab DeruxtecanCapecitabine MonotherapyEnd Results ProgramMerck Co IncNational Cancer InstituteDaiichi Sankyo IncLow Metastatic Breast CancerSolid TumorsPositive Locally AdvancedMetastatic Gastric CancerPositive Metastatic BreastLow Metastatic BreastMutant UnresectableMetastatic SolidReproductive PotentialHepatic ImpairmentPrescribing InformationRare DiseasesCancer ResPlus ExemestaneOestrogen ReceptorNegative Advanced Breast